Titre :

Molecular targets for endogenous glial cell line-derived neurotrophic factor modulation in striatal parvalbumin interneurons.

Auteur(s) :

Enterría-Morales, D. [Auteur]
Hospital Universitario Virgen del Rocío [Sevilla]
Del Rey, N. L. [Auteur]
Hospital HM Puerta del Sur
Blesa, J. [Auteur]
Hospital HM Puerta del Sur
López-López, I. [Auteur]
Hospital Universitario Virgen del Rocío [Sevilla]
Gallet, Sarah [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Prevot, Vincent [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
López-Barneo, J. [Auteur]
Hospital Universitario Virgen del Rocío [Sevilla]
D'anglemont De Tassigny, X. [Auteur]
Hospital Universitario Virgen del Rocío [Sevilla]

Titre de la revue :

Brain Communications

Nom court de la revue :

Brain Commun

Numéro :

2

Pagination :

fcaa105

Éditeur :

Oxford Academic

Date de publication :

2022-07-18

ISSN :

2632-1297

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Administration of recombinant glial cell line-derived neurotrophic factor into the putamen has been tested in preclinical and clinical studies to evaluate its neuroprotective effects on the progressive dopaminergic neuronal ...
Lire la suite >Administration of recombinant glial cell line-derived neurotrophic factor into the putamen has been tested in preclinical and clinical studies to evaluate its neuroprotective effects on the progressive dopaminergic neuronal degeneration that characterizes Parkinson’s disease. However, intracerebral glial cell line-derived neurotrophic factor infusion is a challenging therapeutic strategy, with numerous potential technical and medical limitations. Most of these limitations could be avoided if the production of endogenous glial cell line-derived neurotrophic factor could be increased. Glial cell line-derived neurotrophic factor is naturally produced in the striatum from where it exerts a trophic action on the nigrostriatal dopaminergic pathway. Most of striatal glial cell line-derived neurotrophic factor is synthesized by a subset of GABAergic interneurons characterized by the expression of parvalbumin. We sought to identify molecular targets specific to those neurons and which are putatively associated with glial cell line-derived neurotrophic factor synthesis. To this end, the transcriptomic differences between glial cell line-derived neurotrophic factor-positive parvalbumin neurons in the striatum and parvalbumin neurons located in the nearby cortex, which do not express glial cell line-derived neurotrophic factor, were analysed. Using mouse reporter models, we have defined the genomic signature of striatal parvalbumin interneurons obtained by fluorescence-activated cell sorting followed by microarray comparison. Short-listed genes were validated by additional histological and molecular analyses. These genes code for membrane receptors (Kit, Gpr83, Tacr1, Tacr3, Mc3r), cytosolic proteins (Pde3a, Crabp1, Rarres2, Moxd1) and a transcription factor (Lhx8). We also found the proto-oncogene cKit to be highly specific of parvalbumin interneurons in the non-human primate striatum, thus highlighting a conserved expression between species and suggesting that specific genes identified in mouse parvalbumin neurons could be putative targets in the human brain. Pharmacological stimulation of four G-protein-coupled receptors enriched in the striatal parvalbumin interneurons inhibited Gdnf expression presumably by decreasing cyclic adenosine monophosphate formation. Additional experiments with pharmacological modulators of adenylyl cyclase and protein kinase A indicated that this pathway is a relevant intracellular route to induce Gdnf gene activation. This preclinical study is an important step in the ongoing development of a specific pro-endo-glial cell line-derived neurotrophic factor pharmacological strategy to treat Parkinson’s disease.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Date de dépôt :

2024-06-24T21:26:13Z
2025-02-26T09:05:46Z